Literature DB >> 19582423

Methodologies in assaying prostate cancer stem cells.

Hangwen Li1, Ming Jiang, Sofia Honorio, Lubna Patrawala, Collene R Jeter, Tammy Calhoun-Davis, Simon W Hayward, Dean G Tang.   

Abstract

The cancer stem cell (CSC) theory posits that only a small population of tumor cells within the tumor has the ability to reinitiate tumor development and is responsible for tumor homeostasis and progression. Tumor initiation is a defining property of putative CSCs, which have been reported in both blood malignancies and solid tumors. In order to test whether any given human tumor cell population has CSC properties, the relatively enriched single cells have to be put into a foreign microenvironment in a recipient animal to test their tumorigenic potential. Furthermore, various in vitro assays need be performed to demonstrate that the presumed CSCs have certain biological properties normally associated with the stem cells (SCs). Herein, we present a comprehensive review of the experimental methodologies that our lab has been using in assaying putative prostate cancer (PCa) SCs in culture, xenograft tumors, and primary tumor samples.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582423     DOI: 10.1007/978-1-59745-280-9_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  21 in total

1.  Functional remodeling of benign human prostatic tissues in vivo by spontaneously immortalized progenitor and intermediate cells.

Authors:  Ming Jiang; Douglas W Strand; Suzanne Fernandez; Yue He; Yajun Yi; Andreas Birbach; Qingchao Qiu; Johannes Schmid; Dean G Tang; Simon W Hayward
Journal:  Stem Cells       Date:  2010-02       Impact factor: 6.277

2.  Novel In Vivo model for combinatorial fluorescence labeling in mouse prostate.

Authors:  Xiaolan Fang; Kenneth Gyabaah; Bita Nickkholgh; J Mark Cline; K C Balaji
Journal:  Prostate       Date:  2015-03-08       Impact factor: 4.104

3.  ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone.

Authors:  Amanda G Hansen; Shanna A Arnold; Ming Jiang; Trenis D Palmer; Tatiana Ketova; Alyssa Merkel; Michael Pickup; Susan Samaras; Yu Shyr; Harold L Moses; Simon W Hayward; Julie A Sterling; Andries Zijlstra
Journal:  Cancer Res       Date:  2014-01-02       Impact factor: 12.701

4.  Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7.

Authors:  Can Liu; Kevin Kelnar; Alexander V Vlassov; David Brown; Junchen Wang; Dean G Tang
Journal:  Cancer Res       Date:  2012-06-19       Impact factor: 12.701

5.  Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties.

Authors:  Linlin Zhang; Min Jiao; Lei Li; Dapeng Wu; Kaijie Wu; Xiang Li; Guodong Zhu; Qiang Dang; Xinyang Wang; Jer-Tsong Hsieh; Dalin He
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-12       Impact factor: 4.553

6.  Implication of expression of Nanog in prostate cancer cells and their stem cells.

Authors:  Chen Gong; Hui Liao; Fengjin Guo; Liang Qin; Jun Qi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-04-20

Review 7.  Cancer stem cells and cell size: A causal link?

Authors:  Qiuhui Li; Kiera Rycaj; Xin Chen; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2015-08-01       Impact factor: 15.707

Review 8.  Prostate Stem Cells and Cancer Stem Cells.

Authors:  Jia J Li; Michael M Shen
Journal:  Cold Spring Harb Perspect Med       Date:  2019-06-03       Impact factor: 6.915

Review 9.  Stem cells in genetically-engineered mouse models of prostate cancer.

Authors:  Maho Shibata; Michael M Shen
Journal:  Endocr Relat Cancer       Date:  2015-09-04       Impact factor: 5.678

10.  Dissociated primary human prostate cancer cells coinjected with the immortalized Hs5 bone marrow stromal cells generate undifferentiated tumors in NOD/SCID-γ mice.

Authors:  Xin Chen; Bigang Liu; Qiuhui Li; Sofia Honorio; Xin Liu; Can Liu; Asha S Multani; Tammy Calhoun-Davis; Dean G Tang
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.